

## Index

2D gain and time compensation 24, 25  
 2D shear wave elastography (2D-SWE)  
 26, 157–158, 163–164, 172–180,  
 186–187, 214, 281–283

### a

abdominal factors 234–235, 235–236  
 ablation 273–274  
 abscesses 116–117, 117, 120–121, 121, 206,  
 271–273, 271–272  
 absorption 4  
 acalculous cholecystitis 91, 92, 120,  
 238, 239  
 acoustic impedance Z 2, 3, 4  
 acoustic radiation force impulse  
 (ARFI) 156–158, 163, 187–188  
 acoustic shadowing 20, 20, 26  
 acoustic through transmission 26  
 acquired diffuse liver disease  
 194–196, 195–196  
 acquired immunodeficiency syndrome  
 (AIDS) 122–123, 122  
 acute Budd–Chiari syndrome 216  
 acute cholangitis 103, 104, 205  
 acute fulminant liver failure 150, 151  
 acute presentation of liver dysfunction  
 236–244, 237–244  
 acute viral hepatitis 195  
 adenoma 197, 199, 200  
 adenomyomatosis 92–94, 94  
 advancing technologies  
 279–285, 280–284  
*Aedes aegypti* 123, 123  
 AIDS *see* acquired immunodeficiency  
 syndrome  
 AIH *see* autoimmune hepatitis  
 ALA *see* amoebic liver abscess  
 Alagille syndrome 192  
 alcohol-related liver disease 137, 138–139,  
 169, 169, 173–175, 178–179, 178  
 aliasing 21  
 alveolar echinococcosis 110–112,  
 111–112  
 amoebic liver abscess (ALA) 108, 112–113,  
 112, 116, 271  
 anatomical aspects  
 biliary system 83–85  
 normal liver 27–51

anechoic 26  
 aneurysms 210, 218–219, 225, 246, 248,  
 260, 260  
 annotations/body markings 25  
 anticoagulant dosage 266, 267  
 appendicitis 206  
 ARFI *see* acoustic radiation force impulse  
 array ultrasound transducers 7, 7–8  
 artefacts in ultrasound imaging  
 18–22, 19–22  
 arterial phase focal lesion CEUS 58–81,  
 59–60, 60–80  
 arteriohepatic dysplasia 192  
 arteriovenous fistulae 210, 218–219  
 A-scan measurements 7  
 ascariasis 115, 116  
*Ascaris lumbricoides* 115, 116  
 ascites  
 chronic liver disease 124, 130–137,  
 130–134, 141–146, 148, 148–151  
 normal liver anatomy 27, 51  
 paediatric population 191, 194  
 shear wave elastography 166, 172,  
 178–179, 178  
 aspartate aminotransferase (AST) 179, 178  
 aspiration 269, 271–277, 271–274  
 asthenic 29  
 asthma 233  
 atresia 103  
 attenuation 4–5, 2, 19–21, 20  
 chronic liver disease  
 127, 127–128, 141  
 shear wave elastography 156–159,  
 157–158, 163, 179, 282–283, 283  
 autocorrelation estimators 14  
 autoimmune hepatitis (AIH) 139–140,  
 140, 180–181, 181–182, 186  
 autoimmune liver disease 195

### b

bacterial infections 116–120, 117–120  
*Bacteroides* 116  
 bandwidths 5–6, 6  
 B-cell immunodeficiency  
 disorders 148, 148  
 beaver tail liver 34, 35  
 benign lesions 58–69, 59, 60–70, 80, 98–101,  
 99–101, 197–200, 198–200

biliary system 83–106  
 access 275, 276–277  
 anatomical aspects 83–85  
 bile duct cysts 192–193, 193, 194  
 biliary abscesses 206  
 biliary anastomosis 256, 262  
 biliary atresia 103, 191–192, 192  
 biliary cholangitis 103–105, 104–106,  
 141–142, 142, 170–173, 171–172, 175,  
 183, 183–184  
 biliary duct dilatation 97–102, 98–102,  
 191, 205  
 biliary duct inflammation 103–105,  
 104–106  
 biliary hamartomas 102, 103, 193  
 biliary ischaemia 104–105  
 biliary sludge 87, 87–88  
 biliary tree 29–51, 30–32, 35–36, 44,  
 46–47, 83–85, 84–85, 102–105,  
 103–105, 191–194, 202  
 chronic liver disease 124–126, 141–149,  
 142–145, 150  
 congenital pathologies 102–105,  
 103–105  
 contrast-enhanced ultrasound  
 87–90, 88, 90, 94–97, 96, 100,  
 103–105, 105  
 gallbladder 83–97, 84–91, 93–97  
 hepatic parenchyma 95–98, 96, 102, 105  
 normal anatomy 83–85  
 obstruction 98–102, 98–102,  
 225–241  
 paediatric population 103, 191–196, 192,  
 194, 196, 203–206  
 pathology 85–92, 102–105, 103–105  
 stent function 101–102, 102  
 topography 83–85, 84–85  
 transplantation 262  
 bilomas 91–92  
 Biopince™ needles 268–269  
 biopsy  
 chronic liver disease 142,  
 148–153, 147–153  
 focal lesions 62, 64, 67, 69, 79–81, 80  
 gallbladder pathology 91  
 hepatobiliary intervention  
 268–271, 269–271  
 needles 268–270, 270

- non-cirrhotic portal hypertension 213–215
- paediatric population 192–194, 197
- pre-procedural imaging 268, 269
- shear wave elastography 156, 165–166, 167, 183–185, 182
- techniques 268
- tropical infections 108, 114–115, 118–120
- vascular liver disease 209, 215, 218
- B-mode ultrasound**
- advancing technologies 279
- biliary system 90, 100
- biopsy 270, 271
- chronic liver disease 130–132, 129–132, 138, 149, 167–168, 173–175
- display 11
- focal lesions 58–80, 60–72, 78–80
- image formation 9–11, 10–11, 14, 14, 18–21, 19–20
- normal liver anatomy 47, 55
- paediatric population 192–193, 195–196, 198–206
- point-of-care ultrasound 226, 240–241, 247
- portal hypertension 130–132, 130–132, 167–168, 173–176, 211–213
- shear wave elastography 156–159, 163, 167–168, 173–175
- vascular liver diseases 211, 213
- body markings 25
- breast cancer metastases 148, 148
- brightness mode *see* B-mode ultrasound
- Brucella abortus* 119
- brucellosis 119–120, 120
- bubble-specific imaging 16, 16
- Budd–Chiari syndrome 32, 124, 210, 215–218, 216–218, 238
- Burkholderia pseudomallei* 118–119
- C**
- callipers, measurement tools 24, 24, 54, 55
- cancer
- see also* hepatocellular carcinoma; tumours
- biliary obstruction 99, 101
- breast metastases 148, 148
- cholangiocarcinomas 60, 77–78, 78, 99, 102
- gallbladder 77–78, 76–78
- transplantation complications 262, 262
- CAP *see* controlled attenuation parameter
- cardiac factors 233, 233–234
- cardiogenic cirrhosis 124, 146, 146
- Caroli disease/Caroli syndrome 102–103, 193, 193
- caudate lobe 34, 35–36
- cavernous haemangiomas 60–62
- CBD *see* common bile duct
- CE *see* cystic echinococcosis
- CECT *see* contrast-enhanced computed tomography
- CEMR *see* contrast-enhanced magnetic resonance
- central venous pressure (CVP) 227, 229, 233, 236, 233, 234, 250
- CEUS *see* contrast-enhanced ultrasound
- channel signals 7–8
- chemotherapy 148, 148
- cholangiocarcinomas 60, 77–78, 78, 99, 102
- cholangiopathy 122, 122
- cholangitis
- biliary system 103–105, 104–106
- chronic liver disease 141–145, 141–145
- paediatric population 195–196, 196
- shear wave elastography 170, 171, 175, 183, 183–184
- cholecystectomy 273, 273
- cholecystitis 87–92, 88–91, 93, 205
- choledochal cysts 193–194, 194
- choledocholithiasis 98, 99–100, 205
- cholelithiasis 85–86, 85–86, 103, 205
- cholestatic liver disease 170, 171, 175, 183, 183–184
- chronic Budd–Chiari syndrome 216–218, 217–218
- chronic cholangitis 103–105, 104–106
- chronic cholecystitis 92
- chronic liver disease (CLD) 124–153, 125–153
- acute fulminant liver failure 150, 151
- aetiology 124–130, 137–147
- alcohol-related 137, 138–139, 169, 169, 173–175, 178–179, 178
- ascites 124, 130–137, 130–134, 141–146, 148–149, 148–151
- biliary system 124–126, 141–147, 142–145, 151
- biopsy 142, 148–153, 147–153
- B-mode ultrasound 130–132, 129–132, 138, 149, 167–169, 173–176
- breast cancer metastases 148, 148–149
- chemotherapy 148, 148
- cholangitis 141–145, 141–145
- cirrhosis 124–130, 132–153, 131–153, 165–188, 165–182
- common variable immunodeficiency 148, 148
- congenital hepatic fibrosis 150–151, 152
- contour profiles 124–126, 126
- contrast-enhanced ultrasound 147
- echogenicity 129, 127–128
- echotexture 124–126, 126, 148, 147–150
- fibrosis 124–125, 137, 142–147, 142, 145, 150–153, 152–153
- fulminant liver failure 150, 152
- gallbladder 124–129, 126, 129–131, 145, 149, 150
- general ultrasonic features 124–136, 125–136
- hepatic artery 124, 132–133, 133, 137–138, 149
- hepatic fibrosis 150–151, 152
- hepatic parenchyma 132, 144–146, 145, 148
- hepatic steatosis 126, 127–128, 137–141, 147
- hepatic veins 124–133, 133, 136, 141, 146, 149
- hepatitis 137–141, 140, 169, 176–178
- hepatocellular carcinoma 124, 137, 141
- immunodeficiency disorders 148, 148
- infiltrative neoplastic disease 148–149, 149
- liver failure 124, 137–138, 145–147, 150
- mimics of cirrhosis 124, 146–153, 147–153
- non-alcoholic fatty liver disease 141, 141, 179–180, 185–188
- paediatric population 165, 185
- point-of-care ultrasound 225, 245, 249, 254
- portal hypertension 124–153, 129–144, 146–153, 165–178, 167–169, 173–176, 187–188
- portal venous system 127–153, 129–139, 142–144, 146–153
- primary biliary cholangitis 141–142, 142
- primary sclerosing cholangitis 142–145, 143–145
- pseudo-cirrhosis 148, 148, 149
- sarcoidosis 147, 147
- shape 124–126, 125
- shear wave elastography 165–188, 165–178, 181–182
- sinusoidal obstruction syndrome 149, 150
- size 124–126, 125
- sonography 124–130, 131–145, 137–146, 148–150
- splenomegaly 130–132, 131, 134, 145, 146, 149–152
- subacute liver failure 150, 151
- vascular disorder 151, 152
- vascular modifications 134–135, 135–137
- viral hepatitis 137, 169, 176, 178
- Wilson's disease 145–146, 145
- chronic obstructive pulmonary disorder (COPD) 233
- cineloop functions 24–25
- cirrhosis
- biliary system ultrasound 104–105
- chronic liver disease 124–129, 132–153, 132–153, 165–188, 165–182
- hepatic dysfunction 249–253, 251–253
- mimics 124, 146–153, 147–153
- non-invasive assessments 166–170, 170
- physiopathological background 166–170
- point-of-care ultrasound 225, 232–235, 236, 237, 239, 244, 248–253, 251–253
- portal hypertension 166–170, 170, 209–215, 210
- shear wave elastography 165–188, 165–178, 181–182

- cirrhosis (*cont'd*)  
 sonography 124–130, 132–153, 132–150
- CLD *see* chronic liver disease
- clinically significant portal hypertension (CSPH)  
 chronic liver disease 124, 130, 134–137, 135, 138–139, 150, 151–153  
 point-of-care ultrasound 249  
 shear wave elastography 166–170, 168–174, 176, 179, 181, 186–188
- clip stores 25
- clonorchiasis 115
- Clostridium* 116
- coagulation thresholds 266, **267**
- coaxial techniques 269–270
- colour Doppler  
 advancing technologies 279  
 biliary system 87, 98, 98  
 chronic liver disease 132–133, 132–134, 149  
 focal lesions 197–203, 198–200, 202–206  
 hepatobiliary intervention 258–261, 258–261, 275  
 image formation 14, 14, 21  
 knobology and terminology aspects 24, 26  
 non-cirrhotic portal hypertension 211–212, 213, 216, 218  
 normal liver anatomy 35, 47–49, 48–49  
 paediatric population 197–205, 198–200, 202–205  
 point-of-care ultrasound 241, 250, 253  
 portal hypertension 132–133, 131–134, 211–222, 213, 216, 219  
 shear wave elastography 173, 176  
 transplantation 256–261, 257, 260–261
- common bile duct (CBD)  
 dilatation 97–102, 98–102  
 normal anatomy 30, 30–31, 34, 35, 40–47, 44, 47, 51, 83–84  
 paediatric population 191, 194, 203  
 pathology 92
- common variable immunodeficiency (CVID) 148, 148
- compressional ultrasound waves 1–2, 18
- computed tomography (CT)  
 advancing technologies 279, 283  
 biopsies 268, 274  
 chronic liver disease 148  
 contrast agents 15, 53, 56  
 contrast-enhanced 58–60, 72–81, 211  
 focal lesions 58–62, 70, 77–81, 196–200  
 fusion with MRI 283–284, 284  
 hepatobiliary intervention 266–268, 274  
 non-cirrhotic portal hypertension 213–214  
 paediatric population 196–197  
 point-of-care 248, 247–248  
 transplantation 258–259, 262  
 tropical infections 110, 115–116  
 congenital biliary system pathologies 102–105, 103–105
- congenital cysts 273
- congenital diffuse liver disease 191–194, 193, **194**, 195
- congenital hepatic fibrosis 150–151, 152, 193
- congenital malformations **210**, 219, 219–222
- congenital porto-systemic shunts **210**, 219, 221–222
- congenital vascular malformations **210**, 219, 219–222
- consent 266
- consoles 23–26, 23–26
- continuous wave (CW) Doppler systems 11–14, 12–13
- contour profiles 27–29, 50–51, 124–126, 126
- contrast agents 15–17, 15–17, 53–80, 55, **59–60**, 60–80
- contrast-enhanced computed tomography (CECT) 58–60, **60**, 71–80, 72–80, 211
- contrast-enhanced magnetic resonance (CEMR) 58–60, 72–76, 211
- contrast-enhanced ultrasound (CEUS) 53–56  
 advancing technologies 281  
 benign lesions 58–67, **59**, 60–70, 80  
 biliary system 87–90, 88, 90, 94–97, 96, 100–105, 100, 103–105  
 biopsy 80–81, 75  
 cholangiocarcinomas **60**, 77–78, 78  
 chronic liver disease 147  
 contrast agents 53–81, 55, **59–60**, 60–80  
 data systems 80–81  
 dysplastic nodules **59**, 65, 65, 72  
 fatty sparing/change **59**, 63–64, 64  
 fibrolamellar HCC 72  
 focal lesions 58–81, **59–60**, 60–80, 196–203, 198–203  
 focal nodular hyperplasia **59**, 62, 63  
 gallbladder cancer 77–78, 76–78  
 haemangioma 60–62, 61–62  
 hepatic abscesses **59**, 65–67, 66–68  
 hepatic adenoma **59**, 63  
 hepatic cysts **59**, 60, 60  
 hepatic trauma 67, 70  
 hepatobiliary intervention 270–271, 271  
 hepatocellular carcinoma **59**, **60**, 72–77, 72–77  
 hypervascular metastases **60**, 72  
 hypovascular metastases **60**, 66, 70  
 image optimisation 58–60  
 infection **59**, 65–69, 66–69  
 inflammation **59**, 65–69, 66–69  
 injection 54–59, 55, 71, 75  
 intervention strategies 80  
 knobology and terminology 26, 26  
 late phase 59–78, **59–60**, 63–69, 72–73  
 lesions 58–81, **59–60**, 60–80  
 lymphoma **60**, 78, 79  
 malignant lesions 58–60, 60, 63, 67–78, 71–75  
 measurement tools 54, 55  
 mechanical index 56
- metastases **60**, 66–67, 70–71
- non-cirrhotic portal hypertension **210**, 213–219
- paediatric population 56, 201–203, 198–203
- pharmacokinetics 53
- point-of-care ultrasound 249, 247–248
- protocols 58–60
- quantification 16–17, 17
- regenerative nodules **59**, 65, 65, 72
- reports 80–81
- safety 56
- scanning modes 54, 54
- state of the art 56
- time–intensity curves 17, 17
- transplantation 258–259, 263
- trauma 67, 69, 70
- ultrasound wave interactions 53–54
- vascular liver disease **210**, 213–219
- visualisation 59, 67–68, 80
- contrast resolution 11
- controlled attenuation parameter (CAP) 156–157, 157, 179
- COPD *see* chronic obstructive pulmonary disorder
- Couinaud vascular segmentation classification 32–33, 34
- Cryptosporidium* 122
- CSPH *see* clinically significant portal hypertension
- CT *see* computed tomography
- cutting-type needles 268–269
- CVID *see* common variable immunodeficiency
- CVP *see* central venous pressure
- CW *see* continuous wave Doppler systems
- cystic echinococcosis (CE) 108–110, 109
- cystic fibrosis–associated liver disease 194, 195
- cysts **59**, 60, 60, 110, 193–194, **194**, 272–273
- cytomegalovirus 122
- d**
- delay-and-sum (DAS) receive beamforming 8–9, 9
- Dengue fever 123, 123
- depth controls 24
- destructive imaging 16, 16
- diaphragmatic slips 34, 34
- diffuse liver disease 191–196, 192–193, 195–196
- diffuse steatosis 129
- Doppler effect 11–12, 12
- Doppler ultrasound  
 advancing technologies 279, 280–281  
 artefacts 21–22, 21–22  
 biliary system 87, 98, 98  
 blood flow 11–12, 12  
 challenges with imaging 16  
 chronic liver disease 132–133, 132, 133, 134–136, 136, 149  
 contrast agents 15–17, 15–17  
 flow measurements 11–12, 12

- focal lesions 58–60, 64, 77, 81, 191, 197–206, 198–206
- hepatobiliary intervention 275
- image formation 11–18, 12–18, 21–22, 21–22
- knobology and terminology aspects 24, 25–26
- microvascular flow imaging 25–26, 279, 280, 281
- non-cirrhotic portal hypertension 209–222, **210**, 211–212, 221–222
- normal liver anatomy 35, 47–51, 47
- paediatric population 191, 197–206, 198–206
- point-of-care ultrasound 234, 241, 248, 249, 253
- portal hypertension 132–133, 132–134, 209–222, **210**, 211–212, 221–222
- shear wave elastography 183, 177
- tissue motion velocities 11–12, 12
- transplantation 256–261, 257–261, 263
- tropical infections 110–111, 111
- vascular liver diseases 132–133, 132–134, 209–222, **210**, 211–212, 221
- double reflection artefacts 19–20, 20
- drainage, hepatobiliary 271–274, 271–274
- drug dosage, hepatobiliary 267
- ductal plate malformations 192–194, 193, **194**
- dysplastic nodules **59**, 65, 65, 72
- e**
- echinococcosis 108–112, 109, 111
- Echinococcus* 108–112, 109, 111, 272–273
- echogenicity 27, 50–51, 126–129, 128–129
- echopoor 26
- echotexture 26
- chronic liver disease 124–126, 125, 137–153, 137–140, 145–152
- focal lesions 72, 196–200, 195
- normal anatomy 27, 37, 49
- point-of-care ultrasound 238, 239, 249, 251–253
- shear wave elastography 170–176, 173–175, 181–182, 186
- elastography
- see also shear wave elastography
- image formation 18, 18
- knobology and terminology aspects 26, 26
- vascular liver diseases 209–222, **210**, 214
- Young's modulus 17, 158–159
- emergency/on-call scans 205–206, 206
- emphysematous cholecystitis 91, 91
- Entamoeba histolytica* infections 112–113, 112
- Escherichia coli* 116
- external pressure 156–157, 163–164, 169, 172, 176–183
- extrahepatic disorders
- biliary system ultrasound 84–85
- non-cirrhotic portal hypertension 209–213, **210**, 220–222
- normal anatomy 30
- point-of-care ultrasound 249–254, 251–253
- portal vein obstruction 209–213, **210**
- tropical infections 110
- f**
- FALD see Fontan-associated liver disease
- fascioliasis 114–115, 114
- fast Fourier transform (FFT) 13–14
- fatty sparing/change **59**, 63–64, 65
- fibrolamellar HCC 72, 202
- fibropolycystic liver disease 192–194, 193, **194**
- fibrosis
- chronic liver disease 124–126, 137, 141–153, 142, 145, 152–153
- shear wave elastography 159, 165–170, 165, 167, 170, 172–188, 174, 178, 180, 182–184
- flash haemangiomas 60–62
- flow measurements, Doppler 11–12, 12
- focal fatty sparing/change **59**, 63–64, 65
- focal lesions 58–81, 124, 127, 172, 186–188, 191–206
- aetiology 62, 65
- arterial phase 58–81, 60, **59–60**, 66–80
- benign lesions 58–69, **59**, 60–70, 80
- biliary obstruction 98–101, 99–101
- biopsy 61, 64, 67, 68, 75, 80–81
- B-mode ultrasound 58–81, 60–72, 78, 80
- characterization and detection 58–81
- chronic liver disease 124–126
- colour Doppler 197–203, 198–200, 202–206
- computed tomography 58, 61–62, 67, 78–81, 196–203
- contrast agents 58–81, **59–60**, 60–80
- contrast-enhanced computed tomography 58–60, 72–76
- contrast-enhanced magnetic resonance 58–60, 72–76
- contrast-enhanced ultrasound 58–81, **59–60**, 60–80, 196–203, 198–203
- data systems 80–81
- Doppler ultrasound 58, 60–61, 64, 77, 81, 191, 197–206, 198–206
- fatty sparing/change **59**, 63–64, 65
- infection **59**, 65–69, 66–69
- inflammation **59**, 65–69, 66–69
- late phase 59–79, **59–60**, 63–69, 71–72
- magnetic resonance imaging 58–60, 71, 72, 80, 81, 193–200
- malignant lesions 58–59, **60**, 63, 67, 70–78, 71–79
- metastases **60**, 65, 66, 70–71
- microbubble contrast agents 58–60, 61, 71, 80
- paediatric population 191–192, 196–203, 198–206
- point-of-care ultrasound 241, 246, 243, 247
- portal venous phase 59–81, **59–60**, 66, 68, 74–80
- shear wave elastography 172, 186–187
- ultrasound reports 80–81
- focal nodular hyperplasia **59**, 62, 63, 99, 197, 198
- focal zone number and position 24, 24
- focused ultrasound beams 156–158, 163, 187–188
- Fontan-associated liver disease (FALD) 215
- foodborne infections 113–115, 114
- freeze functions 24–25
- frequency 2–3, 9, 10
- fulminant liver failure 150, 151
- fundamental frequency 9, 10
- fungal abscesses 120–121, 121
- fusion techniques 283, 284
- g**
- gallbladder (GB)
- acalculous cholecystitis 92
- biliary system 85–97, 85–91, 93–97
- bilomas 91–92
- cancer 77–78, 78
- cholecystitis 87–92, 88–91, 93
- cholelithiasis 85–86, 85–86
- chronic liver disease 124–129, 126, 131, 145, 149, 150
- drainage 271–273, 271–273
- emphysematous cholecystitis 91, 91
- gallstones 85–88, 85–88
- gangrenous cholecystitis 87–90, 88–90
- normal anatomy 30, 30, 32, 34, 37–47, 43–44, 51, 83–85, 84–85
- paediatric population 191–192, 194–196, 206
- pathology 85–97, 85–91, 93–97
- practical approach to liver scanning 40–45, 43–44
- sludge 87, 87–88
- topography 83–85, 84–85
- tumours 95–97, 96–97
- wall pathology 92–97, 94–97
- gangrenous cholecystitis 87–91, 88–90
- gas bubble contrast agents 15–17, 15–17
- GB see gallbladder
- Giardia* 122
- Glisson's capsule 27, 29
- gram-negative bacteria 116
- granulomas 67
- greyscale imaging
- advancing ultrasound technologies 279, 281–282
- chronic liver disease 135
- contrast-enhanced ultrasound 54, 59
- focal lesions 197
- normal liver anatomy 27, 47
- paediatric population 203
- portal vein thrombosis 209, **210**
- transplantation 261, 264
- vascular liver diseases 209, **210**, 216, 218–219

**h**

- haemangioendothelioma 197–198, 199  
 haemangiomas 60–62, 61, 62, 99, 110–111, 197–198  
 haemodynamic instability 225, 245, 251, 253  
 hamartomas 102, 103, 199, 199–200  
 harmonic imaging 9, 10  
 HBV *see* hepatitis B  
 HCC *see* hepatocellular carcinoma  
 HCV *see* hepatitis C  
 hepatic abscesses 59, 65–66, 66–67, 108, 112, 112, 116, 206  
 hepatic adenoma 59, 63, 199–200, 200  
 hepatic artery  
   aneurysm 210, 218–219  
   arteriovenous fistulae 210, 218–219  
   chronic liver disease 125, 132, 133, 136, 138, 150  
   intrahepatic aneurysms 210, 218–219  
   normal liver anatomy 29–51, 30–41, 45–49  
   paediatric population 191–193, 197  
   practical approach to liver scanning 45–49, 45–49  
   pseudoaneurysms 260, 260  
   stenosis 210, 259–260, 260  
   thrombosis 210, 258–259, 259  
   transplantation 258–260, 258–260  
   vascular liver diseases 210, 218–219  
 hepatic cysts 59, 60, 60, 61  
 hepatic dysfunction, cirrhosis 249–253, 252–254  
 hepatic fibrosis 150–151, 152, 192–193  
 hepatic metastases 203, 205, 206  
 hepatic parenchyma  
   biliary system 95–97, 96, 102, 105  
   chronic liver disease 132, 145, 146–147, 148  
   focal lesions 64  
   gallbladder tumours 95, 96  
   normal liver anatomy 50  
   paediatric population 191  
   point-of-care ultrasound 248  
   shear wave elastography 169, 176, 181  
 hepatic steatosis 127, 128, 137–141, 147  
 hepatic trauma 67, 69, 70  
 hepatic vasculature 37, 238, 245  
 hepatic veins (HV)  
   chronic liver disease 124–133, 133, 136, 141, 146, 149  
   non-cirrhotic portal hypertension 213–218, 216, 217, 219, 219, 221, 222  
   normal anatomy 32–33, 32–34, 38–51, 38–40, 43–49  
 hepatic venous pressure gradient (HVPG) 129, 153, 166, 178, 186  
 hepatitis  
   chronic liver disease 137–141, 140, 169, 176–178  
   paediatric population 192–195, 195–196  
 hepatitis B (HBV) 137, 169, 176–178, 246  
 hepatitis C (HCV) 74, 137, 137–138, 169, 173, 176–178, 178, 243  
 hepatobiliary intervention 266–277  
   ablation 273–274  
   abscesses 271–272, 271–272  
   access 275, 276–277  
   aspiration 269, 271–273, 271–274  
   authorisation 266  
   biliary access 275, 276–277  
   biopsy 268–271, 269–271  
   blood results/thinners 266, 267  
   checklists 266  
   cholecystectomy 273, 273  
   complications 272, 274  
   congenital cysts 273  
   contraindication considerations 268  
   contrast-enhanced ultrasound 270–271, 271  
   cysts 272–273  
   drainage 271–274, 271–274  
   drug dosage 267  
   echinococcal cyst 272–273  
   gallbladder drainage 271–274, 271–274  
   informed consent 266  
   needles 268–270, 270  
   paediatric population 191  
   patient aspects 266–267, 267, 274  
   portal venous access 275  
   pre-procedural biopsy imaging 268, 269  
   thermal ablation 273–274  
 hepatoblastoma 201, 201–202  
 hepatocellular carcinoma (HCC)  
   biliary duct dilatation 99, 104  
   contrast-enhanced ultrasound 59, 60, 72–77, 73–77  
   hepatobiliary intervention 273–274, 274  
   paediatric population 194, 201–202, 203  
   transplantation 256, 262  
 hepatosplenic sarcoidosis 147, 147  
 hereditary haemorrhagic telangiectasia (HHT) 210, 219, 221  
 herpes virus 122  
 high flow haemangiomas 62  
 HIV and HIV associated diseases 121–123, 121, 122, 122  
 HV *see* hepatic veins  
 hyperechoic 26  
 hyperreflectivity 26  
 hypersthenic body habitus 29  
 hypertension ultrasound 209–222, 210, 211–212, 221–222  
 hypervascular metastases 60, 70  
 hypoechoic 26  
 hyporefectivity 26  
 hypovascular metastases 60, 66, 71  
 artefacts 18–22, 19–22  
 B-mode ultrasound 9–11, 10–11, 14, 14, 18–21, 19–20  
 continuous wave Doppler systems 11–14, 12–13  
 contrast agents 15–17, 15–17  
 contrast-enhanced ultrasound 16–17, 17  
 delay-and-sum receive beamforming 8–9, 9  
 Doppler ultrasound 11–18, 12–18, 21, 21–22  
 elastography 18, 18  
 knobology and terminology 24–26  
 optimisation 24–25, 58–60  
 pre-processing 8–9, 8  
 receive beamforming 8–9, 9  
 shear wave elastography 18, 18  
 single element ultrasound transducers 6–7, 7  
 immunodeficiency disorders 148, 150  
 infection  
   focal lesions 59, 65–67, 67–69  
   tropical 108–123, 109, 111–112, 114, 116–123, 122  
 inferior vena cava (IVC)  
   Budd–Chiari syndrome 215–218  
   chronic liver disease 124, 146  
   congenital porto-systemic shunts 219  
   normal liver anatomy 29–40, 30–34, 36, 37, 41, 47, 48, 51  
   paediatric population 192  
   point-of-care ultrasound 226–242, 228–229, 235, 232–237, 243, 254, 253, 257–258, 261  
   transplantation 257–258, 261–262  
 infiltrative neoplastic disease 148–149, 149  
 inflammation  
   biliary duct 103–105, 104–106  
   focal lesions 59, 65–67, 66–68  
 informed consent 266  
 injection, contrast agents 54–55, 55, 71, 80  
 intrahepatic aneurysms 210, 218–219  
 intrahepatic biliary tree 30, 84–85  
 intrahepatic congenital porto-systemic shunts 210, 219, 221–222  
 intrahepatic non-cirrhotic portal hypertension 213–215, 214, 216–218  
 intraperitoneal fluid 29, 132, 225, 236, 243  
 ischaemia 104  
 IVC *see* inferior vena cava
- j**  
 jaundice 225, 236–241, 238–241, 244
- k**  
 Kaposi's sarcoma (KS) 121–122, 122  
 Kasai 192  
 Klatzkin tumour 99  
*Klebsiella pneumoniae* 116  
 knobology and terminology aspects 23–26, 24
- i**  
 idiopathic portal hypertension 210, 213–214, 214  
 image/clip stores 25  
 image formation 6–22, 7–22

## L

leptospirosis 120, 120  
 lesions *see* focal lesions  
 line-by-line scanning 7, 7–8  
 liver abscess 271–273, 271–272  
 liver anatomy, normal 27–51  
 liver failure 124, 137, 139, 142–150  
 liver stiffness 156–188, 160–163, 165–178, 182–184  
 liver trauma 245–248, 245–249  
 longitudinal ultrasound 1–2, 2, 17–18, 37–38  
 lung ultrasound 225–234, 229, 235, 230–233, 234–236, 249–254, 253–254  
 lymphomas  
   chronic liver disease 149  
   contrast-enhanced ultrasound 60, 78, 79  
   focal lesions 60, 78, 79  
   gallbladder wall 95  
   paediatric population 206  
   transplantation complications 262  
   viral infections 121, 122

## M

magnetic resonance elastography (MRE) 156, 159, 281  
 magnetic resonance imaging (MRI)  
   advancing technologies 279, 283  
   biliary system 94  
   chronic liver disease 130, 147, 149  
   contrast-enhanced 58–60, 72–78, 211  
   contrast-enhanced ultrasound 53  
   focal lesions 58–60, 62, 67, 69, 76, 80–81, 193–200  
   fusion with CT 283, 284  
   hepatobiliary intervention 268, 274, 274  
   image formation 11, 15  
   non-cirrhotic portal hypertension 215  
   paediatric population 193–200  
   tropical infections 110, 115  
   ultrasound comparisons 11, 15  
 malignant lesions/tumours  
   biliary obstruction 99, 101  
   contrast-enhanced ultrasound 58–60, 60, 61, 62, 67–72, 70–75, 77, 80  
   gallbladder 95–97  
   paediatric population 201–205, 203–206  
   transplantation complications 262, 262  
 MASLD *see* metabolic-dysfunction associated steatotic liver disease  
 measurement tools 24, 24, 54, 55  
 mechanical index (MI) 16, 16–17, 56, 59  
 melioidosis 118–119, 119  
 mesenchymal hamartoma 199, 200  
 metabolic-dysfunction associated steatotic liver disease (MASLD) 141, 179–180, 194–195  
 metastases  
   breast cancer 148–149, 149  
   chronic liver disease 148–149, 149

  focal lesions 60, 66, 70–71  
   metastatic neuroblastoma 203, 205  
   paediatric population 203, 205  
 MFI *see* microvascular flow imaging  
 MI *see* mechanical index  
 microbubble contrast agents 16, 16–17, 53–60, 61, 71, 80–81  
 micrometastases 148, 149  
*Microsporidium* 122  
 microvascular flow imaging (MFI) 26, 279, 281, 282  
 mimics of cholecystitis 92, 93  
 mimics of cirrhosis 124, 146–153, 147–153  
 Mirizzi syndrome 98  
 mosquitos 123, 123  
 MRE *see* magnetic resonance elastography  
 MRI *see* magnetic resonance imaging  
*Mycobacterium tuberculosis* 117–118, 118

## N

NAFLD *see* non-alcoholic fatty liver disease  
 NASH *see* non alcoholic steatohepatitis  
 needles 268–270, 270, 272, 272, 274–277, 274  
 neonatal liver ultrasound 191–192  
 neoplastic disease 148–149, 149, 262, 262  
 neuroblastoma 203, 204  
 nodular hyperplasia 59, 62, 63, 99, 197, 198, 214, 218  
 nodular regenerative hyperplasia (NRH) 148, 153, 153, 213  
 noise aspects 18  
 non-alcoholic fatty liver disease (NAFLD) 141, 141, 179–180, 185, 187, 194  
 non alcoholic steatohepatitis (NASH) 174, 187, 195, 282  
 non-cirrhotic portal hypertension 213–215  
 non-linear microbubble behaviour 16–17, 16–17  
 non-lithiatric causes, biliary obstruction 98–101, 99–101  
 non-obstructive sinusoidal dilatation 215  
 normal anatomy  
   ascites 27, 51  
   biliary system 83–85  
   biliary tree 29–51, 30–32, 37, 44, 47, 83–85, 84–85  
   borders 27–29  
   caudate lobe 34, 35–36  
   common bile duct 30, 31, 34, 36, 40–47, 44, 46, 51, 83–84  
   diaphragmatic slips 34, 34  
   Doppler ultrasound 35, 47–51, 49  
   gallbladder 29–30, 30–31, 34, 34–47, 43–44, 51, 83–85, 84–85  
   Glisson's capsule 27, 29  
   hepatic arterial supply 29–51, 30–40, 44–49  
   hepatic veins 32–33, 32–34, 38–51, 37–40, 43–48  
   inferior vena cava 29–40, 30–34, 36, 40, 45–47, 51  
   liver 27–51  
   location 27–29, 28

  pancreas 30, 31, 34, 36, 45, 46, 51  
   papillary process 34, 37  
   parenchyma assessments 37–40, 39–43, 51  
   portal vein 29–33, 31–33, 36, 40–51, 41–48  
   practical approach to liver scanning 34–49  
   Riedel's lobe 34, 35  
   segmentation  
   classification 32–33, 33–34  
   shape/size 27–29, 28, 50–51  
   spleen 30, 31, 34, 35, 49, 50  
   suspensory system 27, 29, 29  
   ultrasound reports 50–51  
   variants of 34  
   vascular anatomy 29–51, 30–50  
 NRH *see* nodular regenerative hyperplasia

## O

on-call scans 205–206, 207  
 on/off control button/switches 23  
 opisthorchiasis 115  
 paediatric population 191–208  
   acquired diffuse liver disease 194–196, 195–196  
   acute viral hepatitis 195  
   aetiology 191, 193  
   Alagille syndrome 192  
   autoimmune liver disease 195  
   benign lesions 197–200, 198–200  
   biliary system 103, 191–196, 192, 194, 196, 202–205  
   biopsy 192, 197  
   B-mode ultrasound 192–193, 195–196, 198–206  
   cholangitis 195–196, 196, 205  
   chronic liver disease 165, 185  
   common bile duct 191, 194, 203  
   congenital diffuse liver disease 191–194, 193, 194, 195  
   contrast-enhanced ultrasound 56, 202–203, 198–203  
   cystic fibrosis-associated liver disease 194, 195  
   diffuse liver disease 191–196, 192–193, 195–196  
   Doppler ultrasound 191, 197–205, 198–206  
   ductal plate malformations 192–194, 193, 194  
   emergency/on-call scans 206, 207  
   fibropolycystic liver disease 192–194, 193, 194  
   focal lesions 191–192, 196–205, 198–206  
   focal nodular hyperplasia 197, 198  
   gallbladder 191–192, 194–196, 205  
   haemangioendothelioma 197, 199  
   haemangioma 197  
   hamartoma 199, 200  
   hepatic adenoma 199, 200  
   hepatic fibrosis 192–193  
   hepatic metastases 203, 204, 205, 205

paediatric population (*cont'd*)  
 hepatitis 192–195, 196  
 hepatobiliary scanning 191  
 hepatoblastoma 201, 201–202  
 hepatocellular carcinoma  
 194, 201–202, 203  
 magnetic resonance imaging  
 193, 196–197, 202  
 malignant tumours 201–203,  
 205, 202–205  
 mesenchymal hamartomas 199, 200  
 non-alcoholic fatty liver disease  
 194–195  
 on-call scans 205–206, 206  
 parenchyma assessments 191–203,  
 193, 204  
 portal hypertension 193–195, 206  
 rhabdomyosarcoma 202–203, 204  
 sclerosing cholangitis 195–196, 196  
 shear wave elastography 165, 185  
 tumours 196–203, 198–203  
 undifferentiated embryonal  
 sarcoma 202, 203  
 viral hepatitis 195  
 Wilson's disease 194

**P**

parasitic infections 108–116, 109, 111–113,  
 114, 116  
 parenchyma assessments 37–40, 38–42,  
 51, 191–203, 193, 204  
 parenchymal abnormalities  
 262–263, 263  
 parenchymal micronodularities  
 126, 127, 139  
 patient aspects 23, 38, 50–51, 266–267,  
 267, 274  
 peliosis hepatis 215  
 peribiliary fibrosis 106, 125, 145  
 perihepatic complications 263, 264  
 periportal fibrosis 129, 150–151,  
 152  
 PH *see* portal hypertension  
 pharmacokinetics 53  
 Phrygian cap gallbladder 83–84, 84  
 piezoelectric effect/materials 5–7, 5–7  
 plot time-enhancing curves 56  
 plugged biopsies 270  
 point-of-care ultrasound (POCUS)  
 225–255, 226, 228–253  
 abdominal factors 234, 235–236  
 acute presentation of liver dysfunction  
 236–241, 237–244  
 basic principles 254  
 basics of 225  
 cardiac factors 233, 233–234  
 central venous pressure 227, 229, 233,  
 233, 250  
 chronic liver disease 225, 245,  
 247–248, 254  
 cirrhosis 225, 234, 235, 236, 238,  
 249–253, 249–253  
 co-existing pathologies 233–234, 233–236

complications 245, 245–246  
 confounding factors 233–234, 233–236  
 examination techniques 226–233,  
 228–229, 235  
 haemodynamic instability  
 225, 246, 249–254  
 hepatic dysfunction 249–253, 252–254  
 inferior vena cava 226–241, 228–229, 235,  
 231–236, 241, 253, 253, 257–258, 261  
 liver trauma 245–246, 247–248  
 post-procedural complications  
 245, 245–246  
 respiratory assessments 225–234, 229,  
 235, 230–237, 249–254, 250–253  
 thoracic factors 233  
 training requirements 225  
 trauma 245–246, 247–248  
 worsening liver function  
 249–253, 250–253  
 point shear wave elastography (pSWE)  
 157–164, 171, 172, 176–178,  
 178, 183–188  
 polycystic liver disease 193  
 polyps 94–95, 95  
 portal biliopathy 101, 213  
 portal hypertension (PH)  
 B-mode ultrasound 130–132, 130–132,  
 167–168, 173–175, 211–213  
 chronic liver disease 124–153, 129–144,  
 146–153, 165–178, 167–169,  
 173–176, 187–188  
 cirrhosis 166–170, 170, 209–215, 210  
 contrast-enhanced  
 ultrasound 210, 213–219  
 Doppler ultrasound 132–133, 132–134,  
 209–222, 210, 211–212, 221  
 non-cirrhotic 209–222  
 paediatric population 192–195, 206  
 physiopathological background  
 166–170  
 pitfalls 153  
 point-of-care ultrasound 249  
 shear wave elastography 165–188,  
 168–176, 181, 186  
 splenomegaly 130–132, 131, 134, 145,  
 146, 150  
 vascular modifications 134–135, 135–136  
 portal vein (PV)  
 congenital porto-systemic shunts  
 210, 219, 221–222  
 normal liver anatomy 29–34, 31–33, 36,  
 40–51, 41–48  
 obstruction 209–213, 210  
 practical approach to liver scanning  
 45–48, 42–46  
 transplantation 256–261, 261  
 portal vein thrombosis (PVT) 40, 175,  
 209–214, 210, 211–213, 238, 241,  
 260–261  
 portal venous system  
 chronic liver disease 127–154, 129–139,  
 142–144, 146–153  
 focal lesions 59–81, 59–60, 66, 68, 74–80  
 hepatobiliary intervention 275

porto-sinusoidal vascular disorder  
 (PSVD) 151, 153, 152, 153, 210,  
 213–214, 214  
 porto-systemic shunts 210, 219, 220–222  
 post chemotherapy breast cancer  
 metastases 148, 148, 149  
 post-cystic enhancement artefacts 20, 21  
 post-operative transplant imaging  
 257–258, 257  
 post-transplantation lymphoproliferative  
 disease (PTLD) 262, 262  
 power Doppler 14–15, 15, 21, 22,  
 25–26, 51, 279  
 preset configurations 23  
 primary B-cell immunodeficiency  
 disorders 148, 148  
 primary biliary cholangitis 141–142, 142,  
 170, 171–172, 175, 183, 183–184  
 primary sclerosing cholangitis  
 (PSC) 103–105, 104–106, 142–145,  
 143–145, 170, 183–185, 183–184  
 propagation, ultrasound waves 1–9, 16–19  
 pseudoaneurysms 225, 246, 247–248,  
 260, 260  
 pseudo-cirrhosis 148, 148  
 pseudotumours 67  
 pSWE *see* point shear wave elastography  
 pulsed wave (PW) Doppler system 11–15,  
 13–15, 21, 21–22  
 pulse-echo measurement method 7  
 PV *see* portal vein  
 PVT *see* portal vein thrombosis  
 PW *see* pulsed wave Doppler system  
 pyogenic liver abscesses 116–117, 117, 271

**R**

receive beamforming 8–9, 9  
 reflection 3–4, 3–4, 4, 19–20, 20  
 refraction 3–4, 4  
 regenerative nodular hyperplasia  
 169, 181, 182  
 regenerative nodules 59, 65, 65, 72, 169,  
 181, 182  
 Rendu-Weber-Osler Disease 210,  
 219, 219–220  
 RES *see* reticulo-endothelial-specific phase  
 resolution 10–11, 11  
 resonance frequency 5, 6  
 respiratory assessments 225–234, 229, 235,  
 230–237, 249–254, 250–253  
 reticulo-endothelial-specific (RES)  
 phase 59  
 reverberation 19, 19  
 rhabdomyosarcoma 202–203, 204  
 Riedel's lobe 34, 35  
 roundworms 115

**S**

safety aspects 56  
 sarcoidosis 147, 147  
 scattering 4, 4  
 schistosomiasis 113, 114

- sclerosing cholangitis 103–105, 104–106, 142–145, 143–145, 170, 183–187, 183–184, 195–196  
 segmentation classification 33, 33  
 Seldinger drainage technique 271–272  
 septated gallbladder 83, 84  
 serology 110  
 shadowing 20, 20, 26  
 shape aspects 27–29, 28, 51, 124–126, 126  
 shear modulus 17–18, 158–159  
 shear wave dispersion (SWD) 159, 282  
 shear wave displacement 156  
 shear wave elastography (SWE) 156–190  
   acoustic radiation force impulse 156–158, 163, 187–188  
   acquisition protocols 164  
   advancing technologies 281–283, 282–283  
   aetiology 163–166, 170–172, 176–188  
   alcohol-related liver disease 168–169, 169, 173–175, 178–179, 178  
   ascites 166, 172, 178–179, 178  
   attenuation 156–158, 157–158, 163, 179, 282–283, 283  
   autoimmune hepatitis 180–185, 181–182, 186  
   biliary cholangitis 170–173, 171–172, 175, 183, 183–184  
   biopsy 156, 165–170, 167, 182, 183, 185,  
   B-mode ultrasound 156–157, 163, 167–169, 173–175  
   cholangitis 170, 171, 175, 183, 183–184  
   cholestatic liver disease 170, 171, 175, 183, 183–184  
   chronic liver disease 165–188, 165–178, 181–182  
   cirrhosis 165–188, 165–178, 181–182  
   clinically significant portal hypertension 166–170, 168–174, 176, 179, 181, 186–188  
   clinical use 165–176  
   confounding factors/current limitations 159–164, 166  
   echotexture 170–172, 172, 173–175, 181, 182, 186  
   equipment-related variability 166  
   external pressure VCTE 156–157, 163–164, 169, 172, 176–183, 187  
   fibrosis 159, 162–169, 165, 167, 170, 172–188, 174, 178, 180, 182–184  
   focal lesions 172, 186–187  
   focused ultrasound beam ARFI 156–158, 163, 187–188  
   hepatic parenchyma 169, 176, 181  
   hepatic venous pressure gradient 166, 178, 187  
   hepatitis 169, 176–178  
   hepatocellular carcinoma 178, 179  
   image formation 18, 18  
   interpretation 165–176  
   knobology and terminology aspects 26, 26  
   liver steatosis 156–157, 162–163, 179–180  
   magnetic resonance elastography 156, 159, 281  
   magnetic resonance imaging 179–180, 182  
   non-alcoholic fatty liver disease 179–180, 185–188  
   non-invasive assessments 166–170, 170  
   paediatric population 165, 185  
   physical principles 156–159, 158–159  
   physiopathological background 166–170  
   portal hypertension 165–188, 168–176, 181, 186  
   practical advice 187–188  
   primary biliary cholangitis 170, 171–172, 175, 183, 183–184  
   primary sclerosing cholangitis 170, 183–185, 183–184  
   protocols 164  
   shear modulus 17–18, 158–159  
   shear wave speed 156–163, 159–163  
   spleen stiffness 169–178, 170–176, 180–183, 186, 188  
   splenomegaly 169, 171, 172, 174–176  
   steatosis 156–157, 162–163, 179–180  
   stiffness 156–188, 160–163, 165, 167–178, 180, 182–185, 186  
   systemic diseases 165, 170–172, 176, 185–188  
   transient readings 156, 157  
   transplant patients 165, 169, 179, 185–188, 186  
   units of measure 158–159  
   vibration-controlled transient elastography 156–157, 163–164, 169, 172, 176–183, 187–188  
   viral hepatitis 169, 176, 178  
   viscosity 158, 162, 282, 282  
   Young's modulus 17–18, 158–159  
 shear wave speed (SWS) 156–163, 159–163  
 side lobe artefacts 20, 20  
 single element ultrasound transducers 6–7, 7  
 sinusoidal dilatation 215  
 sinusoidal obstruction syndrome (SOS) 149, 150, 210, 214–215  
 sinusoids, porto-sinusoidal vascular disorder 210, 213–214, 214  
 size aspects 27–29, 28, 51, 124–126, 125  
 sliver of liver 34, 35  
 sludge 87, 87–88  
 sonography  
   chronic liver disease 124–130, 131–145, 137–146, 148–150  
   cirrhosis 124–130, 132–153, 132–150  
   Doppler systems 13, 13  
   portal hypertension 124, 130, 137–141, 137–139, 150, 153  
 SonoVue 53–54, 55  
 SOS *see* sinusoidal obstruction syndrome  
 spatial resolution 10–11, 10–11  
 speckles 18–19, 19  
 spectral Doppler  
   artefacts 21, 22  
   image formation 13–14, 13–14, 21, 22  
   knobology and terminology aspects 26  
   normal liver anatomy 47, 48  
   portal hypertension 209, 210, 219  
   transplantation 256–261, 257, 259–261  
 speed of sound 2–3  
 spleen  
   normal liver anatomy 30, 31, 34, 35, 49–51, 50  
   paediatric population 191–192, 195  
   stiffness 169–178, 170–176, 180–183, 186, 188  
 splenomegaly  
   chronic liver disease 130–132, 131, 134, 145, 146, 150–151  
   paediatric population 192–195, 195  
   portal hypertension 130–132, 131, 134, 145–146, 150–151, 153  
   shear wave elastography 169, 171, 172, 174–176  
 stability, contrast agents 56  
 staging liver fibrosis 162–163  
 start-up configurations 23  
 state of the art CEUS 56  
 steatosis 126, 127–129, 129, 137–141, 147, 156, 162–163, 179–180  
 stenosis 210, 259–260, 260  
 stent function 101–102, 102  
 sthenic 29  
 stiffness 17–18, 18, 156–188, 160–163, 165–178, 182–184  
 subacute liver failure 150, 151  
 suction-type needles 269  
 suspensory system 27, 29, 29  
 SWD *see* shear wave dispersion  
 SWE *see* shear wave elastography  
 SWS *see* shear wave speed  
 Symmer's fibrosis 113, 114  
 syphilis 119, 119  
 systemic diseases 165, 170–172, 176, 185–188
- t**  
 tapeworms 108–113, 109, 111–112  
 TB *see* tuberculosis  
 temporal resolution 10  
 terminology aspects 23–26  
 TGC *see* time gain compensation  
 thermal ablation 273–274  
 thoracic factors 233, 234  
 thrombosis 209–213, 210, 258–259, 259  
   portal vein 41, 175, 209–213, 210, 211–213, 238, 241, 260–261  
 time gain compensation (TGC) 24, 25  
 time–intensity curves (TIC) 17, 17  
 TIPS *see* transjugular intrahepatic portosystemic shunts  
 tissue motion velocities 11–12, 12  
 tissue stiffness 17–18, 17



- Todani classification 194, **194**  
topography, biliary system  
83–85, 84–85  
tortuous dilatation 219  
touchpad functions 24–25, 24  
toxocariasis 115  
trackballs 24–25, 24  
transducers *see* ultrasound transducers  
transjugular intrahepatic portosystemic  
shunts (TIPS) 275–277  
transmit beamforming 7, 7–8  
transplantation 256–264  
biliary system 262  
complications 258, 260–262  
contrast-enhanced ultrasound  
258–259, 263  
hepatic artery 258–260, 258–260  
hepatocellular carcinoma 256, 262  
indications for 256  
neoplastic disease 262, 262  
parenchymal abnormalities  
262–263, 263  
perihepatic complications 263, 264  
portal vein system 256–261, 261  
post-operative transplant imaging  
257–258, 257  
pseudoaneurysms 260, 260  
shear wave elastography 165, 169, 179,  
185–187, 186  
surgical techniques 256–257  
transverse ultrasound scans 34–39, 39  
trauma 67, 70, 246–248, 240–247  
trocar drainage technique 271–272  
tropical infections 108–123, 109, 111–112,  
114, 116–123, **122**  
bacterial infections 116–120, 117–120  
biopsy 108, 114–115, 118–120  
Dengue fever 123, 123  
fungal abscesses 120–121, 121  
HIV and HIV associated diseases  
121–123, 122, **122**  
parasitic infections 108–116, 109,  
111–112, 114, 116  
viral infections 121–123, 122–123, **122**  
Tru-Cut® biopsy needles 268  
tuberculosis (TB) 67, 117–118, 118  
tumours  
biliary obstruction 99, 101  
contrast-enhanced ultrasound  
58–60, 60, 63, 67–79, 72–75  
gallbladder 95–97, 96–97  
paediatric population 196–205,  
198–205  
transplantation complications 262, 262
- two-dimensional (2D) gain and time  
compensation 24, 25  
two dimensional shear wave elastography  
(2D-SWE) 26, 172–184,  
187–188, 214  
advancing technologies 282  
confounding factors and  
limitations 163–164  
principles 157–158
- U**  
UES *see* undifferentiated  
embryonal sarcoma  
ultrasound, definitions 1  
ultrasound physics 1–22  
ultrasound reports 49–51, 80–81  
ultrasound transducers 5–15, 19–21  
architecture 6–7, 7  
array devices 7, 7–8  
knobology and terminology  
aspects 23, 23  
line-by-line scanning 7, 8  
paediatric population 191  
piezoelectric effect/materials 5–7, 5–7  
point-of-care ultrasound 226–227  
resonance frequency 5, 6  
single element devices 6–7, 7  
transmit beamforming 7, 7–8  
ultrasound waves  
absorption 4  
acoustic impedance 2, 3, 4  
attenuation 4–5, 2  
contrast-enhanced ultrasound  
interactions 53–54  
density 2–3, 2  
frequency 2–3  
physical process effects 3–5, 3–4  
propagation 1–9, 16–19, 53–54  
reflection 3–4, 3–4, 4  
refraction 3–4, 4  
scattering 4, 4  
speed of sound 2–3  
wavelength 2–3  
undifferentiated embryonal sarcoma  
(UES) 202, 203
- V**  
vascular anatomy 30–51, 31–50  
vascular liver diseases (VLD)  
209–222, 211–214, 216–222, **221**  
aneurysms **210**, 218–219  
Budd–Chiari syndrome **210**,  
215–218, 217–218
- chronic liver disease 151, 152  
congenital malformations  
**210**, 219, 221–222  
contrast-enhanced  
ultrasound **210**, 213–219  
elastography 209–222, **210**, 214  
extrahepatic portal vein obstruction  
209–213, **210**  
Fontan-associated liver disease 215  
hepatic arterial supply  
**210**, 218–219  
hereditary haemorrhagic  
telangiectasia **210**, 219, **221**  
intrahepatic aneurysms  
**210**, 218–219  
malformations **210**, 218–219, 220–222  
peliosis hepatis 215  
portal hypertension 213–218,  
214, 216–218  
portal vein thrombosis 175, 209–214,  
**210**, 211–213  
porto-sinusoidal vascular  
disorder 151, 152  
Rendu–Weber–Osler Disease **210**,  
219, 219–220  
sinusoidal dilatation 215  
sinusoidal obstruction syndrome  
149, 150, **210**, 214–215  
vascular segmentation  
classification 32–33, 33  
vibration-controlled transient elastography  
(VCTE) 156–157, 163–164, 169,  
172, 176–184, 187  
viral hepatitis 137, 169, 176, 178, 195  
viral infections 121–123, 122–123, **122**  
viscosity 158, 162, 282, 282  
VLD *see* vascular liver diseases  
Von Meyenburg complexes 102, 103, 193
- W**  
wavelength 2–3  
whole-liver transplantation 256  
Wilms' tumour 203, 204  
Wilson's disease 145–146, 145, 194  
worsening liver function 249–253,  
251–253
- Y**  
Young's modulus 17–18, 158–159
- Z**  
zoom controls 24, 24